XTL Biopharma Balance Sheet - Quarterly (NASDAQ:XTLB)

Add to My Stocks
$1.76 $0.08 (4.35%) XTLB stock closing price Sep 19, 2018 (Closing)

The financial analysis of a company involves interpreting the income statement, balance sheet and cash flow statements of the company to draw insights like we've done in our XTL Biopharma stock analysis. All three financial statements should be used to measure the financial performance of the company, and should form a part of the XTL Biopharma stock analysis. A company releases its balance sheet every quarter along with its quarterly results. XTL Biopharma had a long term debt of $- at the end of 2018 Q2. To understand the debt servicing capacity of the company, one needs to look at XTL Biopharma operating cash flow and XTL Biopharma revenue also. XTL Biopharma debt to equity ratio is 0.

View and download XTL Biopharma quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Cash1.14M1.02M3.28M6.08M6.32M6.75M2.01M2.32M2.6M3.1M
Marketable Securities4.32M4.52M--------
Receivables----------
Inventory----------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets--2.5M-------
Total Current Assets
6.06M6.04M6.2M6.44M6.79M7.4M2.75M2.93M3.21M3.63M
Property Plant & Equipment----------
Accumulated Depreciation----------
Net Property Plant & Equipment
----------
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Intangibles--------1.1M-
Deposits & Other Assets-------1.12M-1.12M
Total Assets
6.44M6.42M6.58M6.82M7.17M7.79M3.01M4.05M4.33M4.75M
Notes Payable----------
Accounts Payable----------
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses----------
Income Taxes Payable----------
Other Current Liabilities----------
Total Current Liabilities
----------
Mortgages----------
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt----------
Non-Current Capital Leases----------
Other Long-Term Liabilities--2.66M2.91M4.7M-----
Total Liabilities
--2.96M3.2M5.08M4.29M----
Minority Interest----------
Preferred Stock----------
Common Stock Net--13.18M13.18M13.18M-6.62M-6.62M-
Capital Surplus--146.01M146M146M-150.78M-150.78M-
Retained Earnings---155.64M-155.65M-157.24M--154.9M--153.46M-
Treasury Stock----------
Other Liabilities----------
Shareholders Equity6.24M6.19M3.61M3.62M2.09M3.5M2.68M3.82M4.07M4.38M
Total Liabilities & Shareholders Equity6.44M6.42M6.58M6.82M7.17M7.79M3.01M4.05M4.33M4.75M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Apart from balance sheet items, an investor would do well to keep track of the XTL Biopharma stock price by looking at XTL Biopharma historical stock prices. One can compare PE with industry average by looking at the XTL Biopharma PE ratio chart. The common balance sheet items are:

  • Assets: An asset is a resource that a corporation like XTL Biopharma owns and has economic value. The two major types of assets are: fixed assets like real estate, plant and machinery and current assets like cash, marketable securities and inventory. The total asset value for XTLB stock as of 2018 Q2 is $6.44M. Its easy to associate the term with manufacturing companies, which invest a lot in factories and equipment. However, the same cannot be said about tech stocks.
  • Liabilities: The total liabilities of XTL Biopharma for the quarter 2018 Q2 total to $-. Liabilities for a company like XTL Biopharma include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.

XTL Biopharma Balance Sheet - Key Ratios

Current ratio
30.3
Debt to equity ratio
0
Asset turnover ratio
0
Receivables turnover
0